The Impact of Primary Care Supported Shielding on the Risk of Mortality in People Vulnerable to COVID-19: English Sentinel Network Matched Cohort Study
Overview
Authors
Affiliations
Objectives: To mitigate risk of mortality from coronavirus 2019 infection (COVID-19), the UK government recommended 'shielding' of vulnerable people through self-isolation for 12 weeks.
Methods: A retrospective cohort study using a nationally representative English primary care database comparing people aged >= 40 years who were recorded as being advised to shield using a fixed ratio of 1:1, matching to people with the same diagnoses not advised to shield (n = 77,360 per group). Time-to-death was compared using Cox regression, reporting the hazard ratio (HR) of mortality between groups. A sensitivity analysis compared exact matched cohorts (n = 24,752 shielded, n = 61,566 exact matches).
Results: We found a time-varying HR of mortality between groups. In the first 21 days, the mortality risk in people shielding was half those not (HR = 0.50, 95%CI:0.41-0.59. p < 0.0001). Over the remaining nine weeks, mortality risk was 54% higher in the shielded group (HR=1.54, 95%CI:1.41-1.70, p < 0.0001). Beyond the shielding period, mortality risk was over two-and-a-half times higher in the shielded group (HR=2.61, 95%CI:2.38-2.87, p < 0.0001).
Conclusions: Shielding halved the risk of mortality for 21 days. Mortality risk became higher across the remainder of the shielding period, rising to two-and-a-half times greater post-shielding. Shielding may be beneficial in the next wave of COVID-19.
Gu X, Watson C, Agrawal U, Whitaker H, Elson W, Anand S JMIR Public Health Surveill. 2024; 10:e52047.
PMID: 38569175 PMC: 11024753. DOI: 10.2196/52047.
The cost of implementing the COVID-19 shielding policy in Wales.
Sewell B, Farr A, Akbari A, Carson-Stevens A, Dale J, Edwards A BMC Public Health. 2023; 23(1):2342.
PMID: 38008730 PMC: 10680245. DOI: 10.1186/s12889-023-17169-3.
Snooks H, Watkins A, Lyons J, Akbari A, Bailey R, Bethell L Public Health. 2023; 218:12-20.
PMID: 36933354 PMC: 9928733. DOI: 10.1016/j.puhe.2023.02.008.
Stidsen J, Green A, Rosengaard L, Hojlund K Front Endocrinol (Lausanne). 2022; 13:1025699.
PMID: 36303877 PMC: 9592709. DOI: 10.3389/fendo.2022.1025699.
Whitaker H, Tsang R, Button E, Andrews N, Byford R, Borrow R J Infect. 2022; 84(6):814-824.
PMID: 35405169 PMC: 8993757. DOI: 10.1016/j.jinf.2022.04.016.